Who: Pierre Fabre/Atara Biotherapeutics
What: Already partnered on cancer drug Ebvallo in the EU, Middle East, Africa and Asia, Atara licensed rest-of-world rights to...
Pierre Fabre Hopes To Enter US Cancer Space With Atara’s Ebvallo
Deal Snapshot: The French company already holds rights to the allogeneic T-cell therapy in much of the world, but will pay Atara $30m up front to obtain rights in the US, Canada and elsewhere.
